No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
SWTX240621C30000
- 6.20
- 0.000.00%
15min DelayClose Jun 18 09:30 ET
0.00High0.00Low
0.00Open6.20Pre Close0 Volume0 Open Interest30.00Strike Price0.00Turnover1899.70%IV-0.06%PremiumJun 21, 2024Expiry Date6.22Intrinsic Value100Multiplier-5DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.8535Delta0.0327Gamma5.84Leverage Ratio-21.1046Theta0.0000Rho4.99Eff Leverage0.0008Vega
Intraday
- 5D
- Daily
News
Express News | SpringWorks Therapeutics Inc : JP Morgan Cuts Target Price to $64 From $77
GSK, SpringWorks End Collaboration Agreement
Express News | SpringWorks Therapeutics Inc - Termination of License Deal Does Not Trigger Any Payment Obligations on Part of Co/Any Other Material Wind-Down Costs
Express News | SpringWorks Therapeutics Inc - Co Expects That GSK Will Continue Ongoing Clinical Trials Under License Agreement
Express News | SpringWorks Therapeutics Inc - Termination Does Not Affect Co's Rights to Continue Developing or Commercializing Its Products or Product Candidates
Express News | SpringWorks Therapeutics:Deal Termination Between Co & Glaxosmithkline Intellectual Property Development Effective 180 Days After Notice Receipt